Document 0264
 DOCN  M9590264
 TI    A study of anti-retroviral therapy and Pneumocystis carinii (PCP)
       prophylaxis in 80 HIV positive patients with CD4 count less than 250 in
       a primary care setting.
 DT    9509
 AU    Bloch M; Duncombe C; Quan D; Holdsworth House General Practice,
       Darlinghurst, NSW.
 SO    Annu Conf Australas Soc HIV Med. 1994 Nov 3-6;6:259 (unnumbered poster).
       Unique Identifier : AIDSLINE ASHM6/95291835
 AB    STUDY OBJECTIVES: To determine anti-retroviral treatments and PCP
       prophylaxis in a group of HIV positive patients with CD4 < 250 attending
       a general practice. METHODOLOGY: 80 patients were selected by reviewing
       practice records of all HIV positive patients with CD4 count recorded <
       250 having attended the practice within the previous 3 months and having
       had T-cell count measured within the previous 6 months. SUMMARY OF
       RESULTS: Patients were stratified by CD4 count. CD4 < 100: 46% were
       taking no anti-retroviral treatment, 32% mono-therapy, and 21%
       combination treatment. CD4 > 100: 27% were taking no treatment, 63%
       mono-therapy, and 9% combination treatment. CD4 < 100: 89% were taking
       Cotrimoxazole and 15% other PCP prophylaxis. CD4 > 100: 85% were taking
       Cotrimoxazole and 15% nil or other PCP prophylaxis. CONCLUSION: There
       was an unexpectedly high proportion not taking any anti-retroviral
       treatment, especially with CD4 < 100. Of those taking treatment, the
       tendency was to mono-therapy, with Zidovudine the most favoured. There
       was a high percentage of patients taking the most effective PCP
       prophylaxis, Cotrimoxazole, some with sulphur allergy having been
       successfully desensitised.
 DE    Antiviral Agents/*THERAPEUTIC USE  AIDS-Related Opportunistic
       Infections/IMMUNOLOGY/*PREVENTION &  CONTROL  *CD4 Lymphocyte Count
       Drug Therapy, Combination  Human  HIV Seropositivity/*DRUG
       THERAPY/IMMUNOLOGY  Phencyclidine/*THERAPEUTIC USE  Pneumonia,
       Pneumocystis carinii/IMMUNOLOGY/*PREVENTION & CONTROL  Primary Health
       Care  Trimethoprim-Sulfamethoxazole Combination/THERAPEUTIC USE  MEETING
       ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).